- As four vaccines from China undergo human trials, trust and cost issues threaten their widespread supply
- China has promised to meet certain countries’ needs, but ‘vaccine nationalism’ and hostilities with the US may complicate matters
China is among the world’s front-runners in developing Covid-19 vaccines. Its indications that mass production of vaccines is imminent has raised questions about capacity, efficacy and availability.Out of 300 vaccine candidates around the world, nine are in phase 3 human trials, according to the World Health Organization (WHO). Four of those are being produced in China, by Sinovac Biotech, military-affiliated private firm CanSino Biologics, and state-owned China National Biotec Group (CNBG), which has two different shots in development.
If Chinese vaccines are safe and effective, how many can be made?
Uncertainties remain, but Chinese officials are optimistic that the first batch of Covid-19 vaccines will be ready for the general public as early as November or December.